Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Biosimilars News

News
Cost-Effectiveness of Primary Prophylaxis With G-CSF Biosimilars in Patients at Risk of Febrile Neutropenia
06/12/2022

Ellen Kurek

Ellen Kurek
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to optimize febrile neutropenia management among patients with intermediate-to-high risk febrile neutropenia while minimizing costs.
PEG biosimilars may be able to...
06/12/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilar Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer Treated With Chemotherapy
06/09/2022

Ellen Kurek

Ellen Kurek
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark determined that median progression-free-survival with SB3 was comparable with that of reference trastuzumab for patients with HER2-positive metastatic breast cancer treated with chemotherapy.
A research group in Denmark...
06/09/2022
Journal of Clinical Pathways
News
Bevacizumab-bvzr Biosimilar Used Most Frequently for Metastatic Colorectal Cancer in US Oncology Practice, According to Retrospective Cohort Study
06/09/2022

Ellen Kurek

Ellen Kurek
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US oncologists have adopted switching between the bevacizumab reference product and bevacizumab biosimilars as well as using bevacizumab-bvzr in chemotherapy combination regimens.
This study finds that US...
06/09/2022
Journal of Clinical Pathways

Advertisement

News
Outcomes of Treatment With Cancer Biosimilars Found Equal to Those of the Reference Drug in Harvard Systematic Review and Meta-Analysis
05/11/2022

Ellen Kurek

Ellen Kurek
Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...
Study findings show that results of rigorous clinical evaluation of cancer drug biosimilars were statistically indistinguishable when compared with the results of evaluations of the reference drug across subgroups of drugs, cancer types, and...
Study findings show that results...
05/11/2022
Journal of Clinical Pathways
News
Biosimilar vs Referent Trastuzumab for the Neoadjuvant Treatment of ERBB2–Positive Breast Cancer
04/14/2022

Ellen Kurek

Ellen Kurek
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
Biosimilar HD201 demonstrates equal efficacy to referent trastuzumab in total pathological complete response and safety in ERBB2–positive breast cancer, according to results from the TROIKA trial.
Biosimilar HD201 demonstrates...
04/14/2022
Journal of Clinical Pathways
News
Trastuzumab Biosimilars Safe, Effective Among Patients With HER2-Positive Breast Cancer
03/07/2022

Marta Rybczynski

Marta Rybczynski
Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.
Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.
Study findings show that...
03/07/2022
Journal of Clinical Pathways

Advertisement

News
Biosimilars Provide Lower-Cost Alternatives to Biologics Used in Cancer Care
02/25/2022
Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.
Findings from a recent update on currently approved oncology biosimilars suggests that the use of biosimilars might provide competitive, lower-cost alternatives to biologics used in oncology.
Findings from a recent update on...
02/25/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Primary Prophylaxis With Biosimilar Filgrastim for Patients at Risk for Febrile Neutropenia
02/21/2022

Janelle Bradley

Janelle Bradley
Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.
Study findings reveal primary prophylaxis with biosimilar filgrastim-sndz is cost-effective in patients with cancer at intermediate risk for febrile neutropenia.
Study findings reveal primary...
02/21/2022
Journal of Clinical Pathways
News
Conversion to Biosimilar Neutropenia Prophylaxis Generates Cost-Savings and Provides Access to Pancreatic Cancer Treatment
02/11/2022

Janelle Bradley

Janelle Bradley
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar pegfilgrastim-cbqv for neutropenia prophylaxis can generate potential cost-savings and provide budget-neutral expanded access to FOLFIRINOX treatment for patients with metastatic pancreatic cancer.
Conversion to biosimilar...
02/11/2022
Journal of Clinical Pathways

Advertisement

News
Biosimilar Trastuzumab is Cost-Efficient Over Reference Trastuzumab for Metastatic Breast Cancer
02/10/2022

Janelle Bradley

Janelle Bradley
Study findings suggest biosimilar intravenous trastuzumab-dkst is cost-efficient over reference intravenous and subcutaneous trastuzumab in metastatic breast cancer.
Study findings suggest biosimilar intravenous trastuzumab-dkst is cost-efficient over reference intravenous and subcutaneous trastuzumab in metastatic breast cancer.
Study findings suggest...
02/10/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use